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Abstract 
Background: Wilson disease (WD) is an autosomal recessive disease caused by mutations in ATP7B encoding a 
copper transporter. Consequent copper accumulation results in a variable WD clinical phenotype involving hepatic, 
neurologic, and psychiatric symptoms, without clear genotype–phenotype correlations. The goal of this study was 
to analyze alterations in DNA methylation at the whole‑genome level in liver and blood from patients with WD to 
investigate epigenomic alterations associated with WD diagnosis and phenotype. We used whole‑genome bisulfite 
sequencing (WGBS) to examine distinct cohorts of WD subjects to determine whether DNA methylation could dif‑
ferentiate patients from healthy subjects and subjects with other liver diseases and distinguish between different WD 
phenotypes.
Results: WGBS analyses in liver identified 969 hypermethylated and 871 hypomethylated differentially methyl‑
ated regions (DMRs) specifically identifying patients with WD, including 18 regions with genome‑wide significance. 
WD‑specific liver DMRs were associated with genes enriched for functions in folate and lipid metabolism and acute 
inflammatory response and could differentiate early from advanced fibrosis in WD patients. Functional annotation 
revealed that WD‑hypermethylated liver DMRs were enriched in liver‑specific enhancers, flanking active liver pro‑
moters, and binding sites of liver developmental transcription factors, including Hepatocyte Nuclear Factor 4 alpha 
(HNF4A), Retinoid X Receptor alpha (RXRA), Forkhead Box A1 (FOXA1), and FOXA2. DMRs associated with WD progres‑
sion were also identified, including 15 with genome‑wide significance. However, WD DMRs in liver were not related to 
large‑scale changes in proportions of liver cell types. DMRs detected in blood differentiated WD patients from healthy 
and disease control subjects, and distinguished between patients with hepatic and neurologic WD manifestations. 
WD phenotype DMRs corresponded to genes enriched for functions in mental deterioration, abnormal B cell physiol‑
ogy, and as members of the polycomb repressive complex 1 (PRC1). 44 DMRs associated with WD phenotype tested 
in a small validation cohort had a predictive value of 0.9.
Conclusions: We identified a disease‑mechanism relevant epigenomic signature of WD that reveals new insights 
into potential biomarkers and treatments for this complex monogenic disease.
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Epigenetics & Chromatin
*Correspondence:  vmedici@ucdavis.edu 
†Janine M. LaSalle and Valentina Medici have contributed equally to this 
work
2 Division of Gastroenterology and Hepatology, Department of Internal 
Medicine, University of California Davis, Sacramento, CA, USA
Full list of author information is available at the end of the article
Page 2 of 16Mordaunt et al. Epigenetics & Chromatin           (2019) 12:10 
Keywords: Wilson disease, Epigenetics, Copper, DNA methylation, Whole‑genome bisulfite sequencing, Chromatin, 
Liver, Blood, Biomarker, Enhancer
Background
Wilson disease (WD) is an autosomal recessive disease 
caused by copper accumulation mainly in the liver and 
in the brain as a result of mutations affecting the cop-
per transporter gene, ATPase copper transporting beta 
(ATP7B). In healthy individuals, ATP7B contributes to 
copper trafficking within the hepatocyte and is required 
for copper excretion into the biliary tract [1, 2]. How-
ever, while the genetic basis is now better understood, 
WD still represents a clinically challenging and often 
unrecognized condition due to incomplete understand-
ing of in-depth pathogenic mechanisms, lack of a gold 
standard diagnostic test, and ultimately limited treatment 
options [3]. The clinical presentation includes hepatic, 
neurologic, and psychiatric manifestations. The lack of a 
clear correlation between DNA sequence mutations and 
clinical presentation can be attributed to the presence 
of more than 500 mutations combined to impair ATP7B 
copper transporter activity, and the potential presence of 
concomitant modifier genes. The most striking evidence 
that factors aside from genetic mutations affect the phe-
notype is derived from multiple case reports describing 
monozygotic twins affected by WD but presenting differ-
ent phenotypes [4, 5].
DNA methylation is a reversible epigenetic modifi-
cation that is affected by both genetic and non-genetic 
factors such as nutrition and toxin exposure, and acts 
at the interface between genetics and the environment. 
Nutritional factors affect methionine metabolism and 
the global availability of methyl groups for DNA and his-
tone methylation. Animal models of WD show changes 
in methionine metabolism [6, 7] and gene transcript lev-
els in response to dietary provision of methyl donors [8]. 
In particular, copper is known to interfere with expres-
sion and activity of the enzyme S-adenosylhomocysteine 
hydrolase (SAHH) which in turn can affect S-adenosyl-
homocysteine (SAH) levels and DNA methyltransferase 
activity and expression [9].
DNA methylation can be altered at individual loci by 
transcription factor-mediated recruitment of DNA meth-
yltransferases and demethylases, affecting future tran-
scription factor binding efficiencies [10]. Methylation 
at the gene promoter is negatively associated with gene 
expression, while gene body methylation is positively 
associated. In patients with common liver conditions, 
changes in gene-specific DNA methylation patterns have 
been observed in both blood and liver and have been 
correlated with different stages of liver disease severity 
[11]. Although liver and brain are the most affected tis-
sues in WD, copper also increases in blood plasma [12]. 
An increased humoral immune response, a decreased 
cell-mediated immune response, and increases in gamma 
delta + T cells have been found in the blood of WD 
patients, suggesting that both liver and blood may have 
characteristic methylation signatures in WD [13, 14].
There is strong evidence supporting the involvement of 
alterations in methionine metabolism in the pathogenesis 
of WD in animal models and indirect evidence support-
ing a role for the same mechanisms in the onset and pro-
gression of this condition in humans [15]. In the present 
study, we explored the hypothesis that DNA methylation 
patterns both in liver and in the blood can differentiate 
patients with WD of various phenotypic presentation 
from healthy subjects and from subjects affected by other 
liver conditions, including non-alcoholic fatty liver dis-
ease (NAFLD) and primary sclerosing cholangitis (PSC), 
with the ultimate objective of identifying new insights 
into pathogenic mechanisms, diagnostic markers, and 
targets for treatment.
Results
Clinical features of liver samples
A total of 21 liver samples were available for methylome 
analysis, including 6 from healthy controls (HC) under-
going bariatric surgery with normal liver histology, 5 
from subjects with NAFLD (disease controls, DC), and 
10 from patients with WD, including 5 percutaneous 
liver biopsies and 5 from explanted livers, both from cir-
rhosis and acute liver failure patients (Additional file  1: 
Table S1, Additional file 2: Table S2). The median age for 
all subjects was 44 years old (range 22–72, not different 
between the three groups). HC had higher BMIs com-
pared to WD patients since samples were derived from 
bariatric surgery patients. WD patients presented signifi-
cantly more advanced stage of fibrosis compared to the 
other subjects, as expected.
DMRs in liver distinguish WD patients from both healthy 
and disease controls
To identify DNA methylation changes specific to 
WD in liver, samples from WD (n = 10), HC (n = 6), 
and DC (n = 5) subjects were analyzed by WGBS for 
DMRs between each group. 969 hypermethylated and 
871 hypomethylated regions were identified that spe-
cifically differentiate WD from both HC and DC sub-
jects, but not DC from HC subjects (Fig. 1a). Of these 
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WD-specific DMRs, 18 reached genome-wide signifi-
cance by FWER (Table 1). Genes near these 18 DMRs 
included those with known functions in liver develop-
ment (BST1, FOXA1, and VTN) and transcriptional 
regulation (FOXA1, MAFB, MN1, NACC2, ZNF689, 
and ZNF785). Gene ontology analysis of WD-specific 
liver DMRs showed that genes near hypermethylated 
DMRs were enriched in functions related to acute 
inflammatory response, lipid catabolism, and folic acid 
metabolism (Additional file  1: Fig. S1). In contrast, 
genes near hypomethylated DMRs were enriched in 
Fig. 1 Liver DMRs distinguish patients with WD from controls. a WGBS‑derived DMRs differentiating WD from both HC and DC, but not DC from 
HC, were identified (WD n = 10, HC n = 6, DC n = 5). Hypermethylated DMRs have higher methylation in WD, while hypomethylated DMRs have 
lower methylation in WD. b Heatmap of HC, WD, and DC using methylation in WD‑specific liver DMRs. Percent methylation for each sample relative 
to the mean methylation at each DMR is plotted. c Principal component analysis using methylation in WD‑specific liver DMRs. The size of each point 
indicates the fibrosis stage of the patient. Ellipses show 95% confidence intervals. For this and all subsequent figures: DMR, differentially methylated 
region; WD, Wilson disease; WGBS, whole‑genome bisulfite sequencing; HC, healthy control; DC, disease control
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functions related to humoral immune response, fatty 
acid transport, and regulation of glycolysis.
The majority of WD subjects could be clearly distin-
guished from HC and DC subjects on the basis of meth-
ylation levels within WD-specific liver DMRs (Fig.  1b, 
c). Methylation in these DMRs was not associated with 
sex, age, BMI, inflammation, or steatosis (Additional 
file  1: Fig. S2, Additional file  2: Table  S3). In contrast, 
methylation in WD-specific DMRs overall, represented 
by the first principal component, was associated with 
fibrosis (p = 2.5E−4), which can also be observed in 
the heterogeneity within WD samples (Fig.  1c). Indi-
vidually, 23 DMRs (1% of WD-specific DMRs) were 
associated with fibrosis (Bonferroni-adjusted p < 0.05, 
Additional file 2: Table S3). Additionally, 63 (3%) WD-
specific DMRs overlapped with DMRs previously 
identified in a methylation study of fibrosis in NAFLD 
subjects [16]. The majority of individual WD-specific 
DMRs, however, were not significantly associated with 
fibrosis.
To investigate WD-specific DNA methylation changes 
in liver prior to onset of fibrosis, early-stage (stage 0–1) 
patients with WD (n = 3) were compared to HC (n = 6) 
and early-stage DC (n = 4) subjects. 124 hypermethylated 
and 70 hypomethylated regions were identified distin-
guishing early-stage WD patients, which were not associ-
ated with demographic covariates (Additional file 1: Fig. 
S3, Additional file  2: Table  S4). 76 of these early-stage 
regions and 167 associated genes overlapped with WD-
specific liver DMRs identified from all WD patients, 
a significant enrichment (Hyper: p = 5.2E−82, Hypo: 
p = 1.4E−31). Furthermore, in the tx-j mouse model of 
WD, 10 genes selected based on human WD differential 
methylation were significantly differentially expressed 
compared to control in liver at an early stage of pathol-
ogy (q < 0.05, Additional file 1: Table S5). Of these genes, 
Table 1 WD-specific liver DMRs with genome-wide significance and associated genes
FWER, family-wise error rate
Chr Start End CpGs Methylation 
difference (%)
FWER Gene Distance 
to TSS (kb)
Position
chr21 31557558 31560049 156 − 37 < 0.001 TIAM1 0.0 TSS
LOC150051 0.0 TSS
chr12 3199472 3201083 96 − 35 0.004 TSPAN9 122.1 Intron
PRMT8 − 180.3 Upstream
chr9 136050881 136052939 57 − 35 0.008 NACC2 42.3 Intron
UBAC1 − 89.5 Upstream
chr22 27797270 27798795 87 27 0.018 MN1 2.7 Exon
LOC100507657 486.6 Downstream
chr15 99105435 99106614 93 − 13 0.020 SYNM 0.4 Exon
LRRC28 − 144.7 Upstream
chr18 22171324 22172395 66 − 27 0.023 GATA6‑AS1 − 2.4 Upstream
chr21 44456208 44457837 56 29 0.023 LRRC3 0.7 Exon
LRRC3‑AS1 − 0.9 Upstream
chr20 40691316 40693007 60 − 28 0.025 MAFB − 2.1 Upstream
chr9 137461602 137462399 37 − 28 0.028 NSMF − 2.3 Upstream
chr9 136418051 136418847 29 32 0.031 SDCCAG3 − 7.4 Upstream
INPP5E 21.0 Downstream
chr11 66855700 66857160 56 − 32 0.032 LRFN4 − 0.2 Upstream
chr22 39994424 39995559 72 − 24 0.035 FAM83F 0.0 TSS
chr4 15702770 15703332 32 − 28 0.038 BST1 0.0 TSS
chr14 37597362 37599120 65 − 17 0.038 FOXA1 − 2.2 Upstream
chr16 30604376 30605260 48 29 0.043 ZNF689 5.5 Exon
ZNF785 − 18.6 Upstream
chr17 28371994 28372583 59 − 20 0.044 SARM1 0.3 Exon
VTN − 1.6 Upstream
chr9 121772727 121773248 32 23 0.048 DAB2IP 205.6 Exon
TTLL11 320.4 Downstream
chr5 10649279 10650004 64 18 0.049 ANKRD33B 85.0 Exon
DAP 111.3 Downstream
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Gata6, Hdac5, Pmpca, Pnpla7, and Tspan9 were upreg-
ulated, while Foxa1, Mafb, Nacc2, Pcx, and Vtn were 
downregulated. Together these results suggest that meth-
ylation differences detected in human WD liver have 
functional consequences and are related to early patho-
genesis mechanisms rather than a result of late-stage 
fibrosis.
WD‑specific hypermethylated liver DMRs are enriched 
in liver enhancers and flanking active liver promoters
To functionally annotate the WD-specific liver DMRs 
identified from all samples, histone modification ChIP-
seq peaks and chromatin state predictions from 127 cell 
and tissue types in the Roadmap Epigenomics Project 
[17] were compared to DMR chromosomal locations 
for enrichment (Fig.  2). Hypermethylated WD-spe-
cific DMRs were highly significantly enriched for liver 
H3K4me1 and H3K4me3 histone modification marks 
overlapping 87% and 50% of hypermethylated DMRs, 
respectively (H3K4me1 odds ratio = 28.6, false discovery 
rate (FDR) q < 1.0E−319; H3K4me3 odds ratio = 8.8, FDR 
q = 7.6E−210). In contrast, hypomethylated WD-specific 
DMRs were enriched in H3K4me1 and H3K4me3 marks 
across many tissue types. WD-specific liver DMRs were 
next overlapped with ChromHMM chromatin state pre-
dictions, which use histone modification ChIP-seq data 
to segment the genome into 15 functional states. Com-
bined WD-specific DMRs showed significant enrich-
ment in enhancers (Enh, yellow) and regions flanking 
active transcription start sites (TssAFlnk, orange) com-
pared to background across all tissues (Fig.  2b), with a 
markedly pronounced enrichment of these functional 
regions (Fig.  2c). Hypermethylated WD-specific DMRs 
individually were also specifically enriched in liver 
enhancers and regions flanking active transcription start 
sites (Additional file  1: Fig. S4; Enh odds ratio = 11.6, 
FDR q = 5.5E−278; TssAFlnk odds ratio = 10.1, FDR 
q = 3.7E−192). Regions flanking transcribed regions were 
also significantly enriched, but only made up a small por-
tion of hypermethylated DMRs.
WD‑specific hypermethylated DMRs in liver are enriched 
in liver‑associated transcription factor binding sites
To determine the potential association of methylation 
differences at WD-specific liver DMRs with transcrip-
tion factor binding, DMRs were overlapped with tran-
scription factor ChIP-seq peaks in liver from ENCODE 
(Fig. 3a) and assessed for enrichment of known transcrip-
tion factor binding site sequence motifs (Fig. 3b). Hyper-
methylated DMRs were enriched in liver binding sites 
and sequence motifs for HNF4A, RXRA, FOXA1, and 
FOXA2, while hypomethylated DMRs had no enrich-
ment for these factors (Additional file 1: Fig. S5). When 
hypermethylated DMRs overlapping binding sites for 
HNF4A, RXRA, FOXA1, and FOXA2 were compared, 
they were enriched for overlapping the same DMRs, 
including 82 regions containing all four of these factors 
(Fig.  3c, d). One such DMR was at LRRC3, which was 
hypermethylated specifically in WD liver with genome-
wide significance, and contains overlapping liver binding 
sites for all four of these factors (Fig. 3e). 
WD progression‑associated liver DMRs reveal 
dysregulation of complement activation and embryonic 
development pathways with increasing disease severity
To determine the DNA methylation changes in liver 
associated with progression of WD, early (stage 0–1) and 
advanced fibrosis stage (≥ 2) WD patients were com-
pared and assessed for DMRs (early WD n = 3, advanced 
WD n = 7). 1339 hypermethylated and 1119 hypometh-
ylated regions were identified as changing with disease 
progression, and subjects could be separated by stage 
on the basis of methylation in these DMRs (Fig.  4a, b). 
However, methylation was not associated with covari-
ates (Additional file 2: Table S6). Among these WD pro-
gression DMRs, 15 reached genome-wide significance 
(Additional file 1: Table S7). Genes near these significant 
DMRs included those involved in blood coagulation (F7, 
F10), immune activation (RNF123, SIGLEC15) and mito-
chondrial function (KAT2A, LIAS, and SARDH). Func-
tional enrichment analysis of all WD progression DMRs 
revealed that hypermethylated regions were enriched 
for genes involved in complement activation, humoral 
immune response, and lipid homeostasis, while hypo-
methylated regions were enriched for genes involved 
in heart, respiratory, muscle, and endoderm develop-
ment (Fig. 4c). These data suggest that DNA methylation 
alterations of genes associated with complement acti-
vation and embryonic development occur during WD 
progression.
WD‑associated liver DMR genes are enriched in drug 
targets
Identification of genes with differential methylation in 
liver that are associated with WD diagnosis and sever-
ity offers the opportunity to predict therapeutics that 
may interact with these genes and potentially alter WD 
pathology. To identify drugs associated with WD DMRs, 
known drug–gene interactions were obtained from the 
Drug Gene Interaction database [18] and overlapped 
with WD DMR genes (Additional file 2: Table S8). The 
most significantly enriched drug was bepridil, which 
is a calcium antagonist known to affect mitochondrial 
function [19] that interacts with 4 genes with differ-
ential methylation in early-stage WD: ATP1A1, CAC-
NA1H, TNNC1, and VIPR2 (p = 1.2E−4). WD-specific 
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Fig. 2 WD‑specific hypermethylated liver DMRs are enriched in liver enhancers and flanking active liver promoters. a WD liver DMRs were 
overlapped with histone modification ChIP‑seq peaks from the Epigenome Roadmap using LOLA and the odds ratio was plotted for all tissues. b, 
c WD liver DMRs were overlapped with chromatin states from the Epigenome Roadmap using LOLA and the percent of DMRs and background 
regions overlapping each state was plotted as b the mean overlap for all tissues or c overlap for liver
Fig. 3 WD‑specific hypermethylated liver DMRs are enriched in liver‑associated transcription factor binding sites. a WD liver DMRs were overlapped 
with available liver transcription factor ChIP‑seq peaks from ENCODE using LOLA and the odds ratio was plotted and sorted by hypermethylated 
DMR odds ratio. b WD liver DMR sequences were tested for enriched known transcription factor motifs using HOMER and factors with liver 
ChIP‑seq data were plotted. c Hypermethylated WD liver DMRs overlapping with top liver transcription factor ChIP‑seq peaks were overlapped. d 
Transcription factor overlap enrichment. e UCSC Genome Browser view of overlapping transcription factor binding sites and a hypermethylated 
DMR at LRRC3 
(See figure on next page.)
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liver DMR genes were significantly enriched for inter-
actions with melphalan, which has been used to treat 
liver metastases [20] and is associated with the FANCC, 
GSTP1, MGMT, OPLAH, and PLAT genes (p = 6.5E−4). 
Although the effects of these drugs on WD pathology 
cannot be predicted based on this analysis, these data 
Fig. 4 Liver DMRs differentiating early‑ from advanced‑stage patients with WD. WD progression‑associated liver DMRs are enriched for genes 
involved in complement activation and embryonic development. Hypermethylated DMRs have higher methylation in advanced WD, while 
hypomethylated DMRs have lower methylation in advanced WD (early WD n = 3, advanced WD n = 7). a Heatmap using methylation in early 
versus advanced WD liver DMRs. Percent methylation for each sample relative to the mean methylation at each DMR is plotted. b Principal 
component analysis using methylation in early versus advanced WD liver DMRs. Ellipses show 95% confidence intervals. c Results from GREAT 
functional enrichment analysis of early versus advanced WD liver DMRs compared to background. Top 10 terms from gene ontology databases 
for hypermethylated or hypomethylated DMRs with FDR q < 0.05 are shown (dotted line indicates the significance threshold). For this and all 
subsequent figures: FDR; false discovery rate
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do suggest compounds for further investigation in WD 
model systems.
WD‑associated liver methylation is not influenced 
by cell‑type changes
DNA methylation changes observed in a bulk tissue such 
as liver can be affected by differences in proportions of 
individual cell types between samples. To determine 
whether cell-type changes influenced DMRs identified 
in this study, we examined sets of promoters specifically 
hypermethylated in human hepatocytes (HEP), hepatic 
stellate cells (HSC), or liver sinusoidal epithelial cells 
(LSEC) [21]. Out of all of the identified WD DMRs, only 
63 WD-specific, 3 early-stage WD-specific, and 86 WD 
progression DMRs overlapped with cell-type-specific 
methylated promoters (Additional file  1: Fig. S6a). Less 
than 5% of DMRs from each comparison were located at 
a cell-type-specific methylated promoter. Percent meth-
ylation at cell-type-specific promoters was compared 
between all sample groups used to identify DMRs (Addi-
tional file 1: Fig. S6b-d, Additional file 2: Table S9). The 
majority of cell-type-specific promoters were not differ-
entially methylated between any of the sample groups. 
Compared to HC, WD samples were nominally differ-
entially methylated at 7% of HEP promoters, 4% of HSC 
promoters, and 7% of LSEC promoters (p < 0.05). The 
largest effect was observed in advanced compared to 
early-stage WD, where 8% of HEP promoters, 9% of HSC 
promoters, and 13% of LSEC promoters were nominally 
differentially methylated (p < 0.05). These results suggest 
that alterations in cell-type proportions do not have a 
major effect on differential methylation observed in WD 
liver.
DMRs in blood distinguish WD from controls
While the identification of liver WD-specific DMRs is 
most relevant for disease insights, we asked whether a 
similar epigenomic signature could be identified in more 
accessible blood samples as potential WD biomarkers. 
A total of 82 whole blood samples in two independent 
cohorts were available for DNA extraction and methy-
lome analysis (Additional file  1: Table  S10, Additional 
file 2: Table S11). Patients with WD were all recruited at 
the time of diagnosis and not on anti-copper treatment. 
The stage of fibrosis was available, as derived directly 
from liver biopsy or from non-invasive assessment, for 
NAFLD and PSC subjects, ranging from no fibrosis to 
cirrhosis. Whole blood methylomes from WD (n = 40), 
HC (n = 12), and DC (which includes NAFLD and PSC 
patients, n = 20) were assessed by WGBS, and DMRs 
were called for each pairwise comparison (Fig.  5a). 187 
hypermethylated and 75 hypomethylated WD-specific 
DMRs were identified distinguishing WD from both HC 
and DC patients. Using methylation levels in these WD-
specific blood DMRs, the majority of patients with WD 
separated from HC and DC patients (Fig. 5b, c). In con-
trast, methylation in the majority of DMRs was not asso-
ciated with demographic covariates (Additional file  2: 
Table S12).
Due to the enrichment of liver WD-specific DMRs in 
liver enhancers, chromatin state enrichment in blood 
WD-specific DMRs was also assessed (Additional file 1: 
Fig. S7). Overall, DMRs were enriched for immune 
cell enhancer regions, and especially those predicted 
in hematopoietic stem cells, which overlapped 51% of 
DMRs (odds ratio = 9.1, FDR q = 6.1E−58). Additionally, 
hypermethylated regions were enriched more in mono-
cyte, neutrophil, B cell, and natural killer cell enhancers, 
while hypomethylated regions were enriched more in T 
cell enhancers and promoters.
DNA methylation in blood reflects a subset of WD‑specific 
liver DMRs
The number of WD-specific DMRs identified in blood 
was much lower than those identified in liver, as 
expected. However, 99 (22%) of the genes near blood 
DMRs overlapped with those identified in liver, a signifi-
cant enrichment (Hyper: p = 1.1E−25, Hypo: p = 2.0E−6, 
Additional file  1: Fig. S8a). Genes near the 10 DMRs 
with overlapping locations and common direction in 
blood and liver included CSAD, ITGB7, LSM12, PSMD9, 
RRN3P2, SNX29P2, and PFN3. In particular, a liver DMR 
in an intron of HDAC5 and upstream of LSM12 was spe-
cifically and significantly hypermethylated in WD liver 
and blood (Additional file 1: Fig. S8b–d).
Human and mouse WD DMR genes overlap 
within and across tissues
To determine whether DMR genes associated with 
ATP7B loss of function are conserved between humans 
and mice, human DMR genes in liver and blood were 
overlapped with DMR genes previously identified in fetal 
liver of the WD model tx-j mice compared to wild-type 
C3H mice (Additional file  1: Fig. S9, Additional file  2: 
Table  S13) [15]. Twenty genes were differentially meth-
ylated in the same direction in both human liver and 
mouse fetal liver (hyper: q = 7.7E−2, hypo: q = 4.7E−4). 
Among the genes with conserved differential methylation 
upon ATP7B loss of function were ALKBH5, GRID2IP, 
KDELR2, CACNA1H, CAMK2B, and WNT11. In blood, 
7 genes were differentially methylated in the same direc-
tion as mouse fetal liver (hyper: q = 6.6E−3, hypo: 
q = 1.3E−1). Of these, ZNF750 and MAD1L1 were also 
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differentially methylated in human liver. The conserved 
differential methylation of these genes suggests they rep-
resent important early perturbations in WD pathology.
DMRs in blood distinguish patients with hepatic 
and neurologic WD phenotype
Phenotypic variation is an important feature of WD that 
is not explained by genotype, so we analyzed methyla-
tion in blood to determine whether DMRs were present 
that differentiated WD patients with hepatic (WDH) 
and neurologic (WDN) symptoms (WDH n = 20, WDN 
n = 20). A total of 1346 regions were hypermethylated, 
while 1514 regions were hypomethylated in WD patients 
with hepatic symptoms compared to those with neu-
rologic symptoms (Fig.  6a, b). Patients could clearly be 
clustered by phenotype, suggesting epigenetic differ-
ences exist in the blood that are associated with WD 
symptoms. In contrast, methylation in WD phenotype 
DMRs was not associated with covariates (Additional 
file  2: Table  S14). Genes near all DMRs were enriched 
for functions in abnormal B cell physiology, while those 
near regions  hypomethylated in WDH were enriched 
for functions in dementia, mental deterioration, and 
for belonging to the chromatin-modifying polycomb 
Fig. 5 Blood DMRs distinguish patients with WD from controls. a WGBS‑derived DMRs differentiating WD from both HC and DC, but not DC from 
HC, were identified (WD n = 40, HC n = 12, DC n = 20). b Heatmap of HC, WD, NAFLD, and PSC blood using methylation in WD‑specific blood DMRs. 
Percent methylation for each sample relative to the mean methylation at each DMR is plotted. c Principal component analysis using methylation in 
WD‑specific blood DMRs. Ellipses show 95% confidence intervals
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repressive complex 1 (PRC1) (Fig.  6c). Resembling the 
WD-specific blood DMRs, WD phenotype DMRs were 
enriched in immune cell enhancers, and especially those 
in hematopoietic stem cells (Additional file 1: Fig. S7c, d). 
Uniquely, WD phenotype DMRs were enriched in biva-
lent enhancers, which are defined by both H3K4me1 and 
H3K27me3 and regulated by PRC1, and were especially 
enriched in T cells (odds ratio = 4.6, FDR q = 1.5E−171).
WD phenotype blood DMRs classify hepatic 
and neurologic WD in independent cohort
Distinguishing between WD phenotypes using blood-
based biomarkers has a potential application in patient 
diagnostics. To assess the accuracy of the identified WD 
phenotype blood DMRs to classify WD patients as either 
the hepatic or neurologic form, an Adaboost classifier 
was trained on blood methylation in these regions in the 
original patient cohort and tested on an independent 
cohort (WDH n = 5, WDN n = 5). 44 DMRs were identi-
fied with feature importance greater than zero and were 
used in the model (Fig.  7a, b). Genes near these DMRs 
included several with known neurologic function, such 
as CHRNB3, CYP46A1, GALR1, LHX4, NGF, NPTXR, 
SHH, and WNT7B, and hepatic function, including ONE-
CUT1 (Fig. 7c, Additional file 2: Table S15). Importantly, 
the classifier was able to correctly identify all but one of 
the independent test samples as having either the hepatic 
or neurologic form of WD (precision = 0.9, receiver 
Fig. 6 Blood DMRs distinguish patients with hepatic (H) or neurologic (N) WD. DMRs differentiating WDH from WDN were identified. a Heatmap 
using methylation in WDH versus WDN blood DMRs. Percent methylation for each sample relative to the mean methylation at each DMR is 
plotted (WDH n = 20, WDN n = 20). b Principal component analysis using methylation in WDH versus WDN blood DMRs. Ellipses show 95% 
confidence intervals. c Results from GREAT functional enrichment analysis of WDH versus WDN blood DMRs compared to background. Terms from 
gene ontology databases with FDR q < 0.05 are shown, with a dotted line indicating the significance threshold. “All DMRs” (green) refers to both 
hypermethylated and hypomethylated DMRs; “Hypomethylated DMRs” (blue) refers to DMRs with lower methylation in WDH compared to WDN
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operating characteristic (ROC) area under the curve 
(AUC) = 0.8, Fig. 7d). These results suggest that WD phe-
notype can be identified in patients using blood DNA 
methylation in these 44 regions.
Discussion
This is the first study to investigate methylation changes 
in patients with WD at a genome-wide level through 
WGBS. This epigenomic signature reveals methylation 
changes occurring over liver-specific enhancers and tran-
scription factor binding sites, demonstrating that WD 
is a genetic disease whose progression and, potentially, 
pathogenesis is associated with epigenetic changes. We 
demonstrate a specific liver pathogenesis-related DNA 
methylation signature in patients with WD compared 
to healthy subjects and subjects with other liver dis-
eases. A subset of these DNA methylation differences 
were identified both in the liver and in the blood from 
distinct cohorts of patients, supporting the premise 
that methylation markers in the blood can be reflective 
of disease pathogenesis in another tissue. Furthermore, 
DNA methylation differences also distinguished patients 
on the basis of hepatic versus neurologic presentation, 
specifically at genes encoding epigenetic factors with 
Fig. 7 Selected WD phenotype blood DMRs classify hepatic from neurologic WD in an independent test cohort. A classifier using the AdaBoost 
algorithm was trained with methylation values at WD phenotype DMRs in WD patient blood (WDH n = 20, WDN n = 20). a Feature importance was 
determined for each of the 2860 DMRs after training. b Heatmap of 44 DMRs used in classifier using methylation in training samples. c Genes near 
DMRs with feature importance ≥ 0.04. d Classification results in test cohort of WD patients. In the plot, the column represents true phenotype, while 
the color represents predicted phenotype (WDH n = 5, WDN n = 5, precision = 0.9, ROC AUC = 0.8)
Page 13 of 16Mordaunt et al. Epigenetics & Chromatin           (2019) 12:10 
mechanistic significance, such as those in PRC1. A small 
subset of these regions could classify WD patient pheno-
types in an independent cohort, demonstrating the diag-
nostic potential of DNA methylation. This epigenomic 
signature of WD reveals insights into gene pathways, 
gene–drug interactions, and potential biomarkers that 
may be clinically useful in early intervention and treat-
ment of WD.
Our previous data in the tx-j mouse model of WD 
demonstrated a global reduction of hepatic cell growth 
and maturation deficiency in fetal livers, alleviated by 
maternal dietary supplementation with the methyl donor, 
choline [22]. Differential methylation was also observed 
in fetal liver of tx-j mice, which was ameliorated by cho-
line supplementation [15]. Differentially methylated 
genes identified in patient livers significantly overlapped 
with those in tx-j fetal liver and included several genes 
encoding transcription factors important in liver devel-
opment. GATA6 is involved in multiple stages of liver 
maturation and highly expressed in hepatocytes during 
early fetal development [23]. FOXA1 is crucial in initiat-
ing specification during liver embryogenesis [24] and is 
also expressed in adult livers, whereas VTN, a FOXA1 
target gene, is involved in embryonic stem cell matura-
tion [25] and has been shown to be upregulated in fetal 
hepatic stellate cells [26]. Gata6, Foxa1, and Vtn were 
also found to be differentially expressed in adult tx-j liver. 
These DNA methylation signatures of WD point to liver 
development and regeneration pathways which could be 
in turn affected by methyl donor dietary factors both in 
the fetal and adult life.
Hypermethylated DMRs identified in WD were spe-
cifically enriched in liver-specific enhancers and tran-
scription factor binding sites, which is a novel finding for 
the WD field. Hypermethylated DMRs in liver-specific 
enhancers may reflect specific deficits in enhancer usage 
or HNF4A binding. HNF4A is a crucial transcription 
factor in hepatocyte maturation, necessary to maintain 
the epithelial phenotype of hepatocytes [27]. A previous 
report showed impaired binding of HNF4A and RXR to 
promoter response elements in patients with WD [28]. 
In addition, dysregulation of liver X receptor/retinoid 
X receptor was implicated in the pathogenesis of WD 
[29]. Liver binding sites for HNF4A, RXR, FOXA1, and 
FOXA2 were found to overlap at a significantly hyper-
methylated WD-specific liver DMR in the promoter of 
LRRC3. Another DMR at LRRC3 was significantly hyper-
methylated in advanced compared to early-stage WD. 
Previously, LRRC3 has been associated with susceptibil-
ity to platinum-induced liver injury and oxidative stress 
[30]. Our results demonstrating hypermethylation over 
HNF4A and other transcription factor binding sites 
within liver-specific enhancers and promoters provides a 
new potential explanation for these prior molecular find-
ings in WD pathogenesis.
In addition, the insights gained from this epigenomic 
study of WD may shed light on the controversial rela-
tionship between copper accumulation and potentially 
reduced risk of liver cancer in WD [31, 32]. Among the 
most striking findings were that the DMR genes over-
lapping between liver and blood have major roles in 
epigenetic mechanisms in cancer. In particular, HDAC5 
activation is implicated with hepatocyte proliferation 
and hepatocarcinogenesis [33] and has been involved 
in lipid metabolism and fatty acid oxidation [34]. Both 
NCOR2 and CTBP2 were hypermethylated in liver and 
blood of WD patients and function as transcriptional 
co-repressors that are dysregulated in cancer. NCOR2 
interacts with both nuclear receptors, including LXR 
and RXR, and class IIa HDACs, such as HDAC5 [35, 36]. 
NCOR2 is also differentially expressed in bladder, breast, 
and prostate cancers [35]. CTBP2 functions to recruit 
PRC2 proteins to add H3K27me3 during differentiation 
and also interacts with HDACs [37]. Further, CTBP2 
is overexpressed in prostate cancer and associated with 
tumor progression [38]. Other genes, including GATA2, 
GADD45B, and MIR126, are differentially methylated in 
WD liver and blood, also play a role in epigenetic mecha-
nisms in cancer. The dysregulation of these epigenetic 
regulators in WD may impact the susceptibility of these 
patients to cancer.
Several prior studies have attempted to identify specific 
DNA methylation changes in whole blood or peripheral 
blood mononuclear cells (PBMCs) as indicators of liver 
disease. In particular, analyses of patients with NASH 
identified DNA methylation changes over genes associ-
ated with collagen content [11] and steatosis [39]. Our 
in-depth analysis identified DMRs that could differentiate 
early- from advanced-stage WD and hepatic from neuro-
logic phenotypes at the time of diagnosis. To our knowl-
edge, this is the first study identifying a combination of 
pathogenesis-meaningful markers with the potential to 
contribute to the diagnosis in association with clinical 
and genetic parameters. In our analysis of advanced com-
pared to early WD liver samples, we identified hyper-
methylated genes involved in the complement pathway, 
which were previously shown to be serum biomarkers of 
WD [40]. Our study describes a set of differentially meth-
ylated genes from whole blood overlapping with those 
identified in WD liver, suggesting that these loci could be 
pursued as potential blood biomarkers of WD at various 
stages of disease progression in future studies.
Limitations of this study include the use of whole blood 
and whole liver tissue, as both are mixtures of many dif-
ferent cell types. The influence of cell type was assessed 
in liver, where it was found that the large majority of 
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promoters hypermethylated in specific liver cell types 
were not associated with differential methylation in WD 
liver. A second limitation was the lack of liver controls 
from individuals of a healthy weight. This was controlled 
for by examining BMI, which was not associated with 
DMR methylation. The changes in DNA methylation of 
genes in pathways related to fatty acid oxidation and lipid 
catabolism are consistent with prior evidence of down-
regulated lipid metabolism pathways in WD animal mod-
els [8]. A third limitation was the relatively low coverage 
of the methylation analysis which may limit the ability to 
detect all possible methylation differences. However, the 
relatively large number of samples allowed us to capture a 
large number of DMRs that were validated in independ-
ent cohorts providing the proof of principle of a role for 
DNA methylation in WD. In addition, the significant 
costs of the described sequencing methodologies could 
be seen as limiting factor to the future applicability of 
DMR markers as diagnostic tests for WD. Using reduced 
representation of specific WD predictive DMRs will sig-
nificantly reduce the costs, increase the sequencing cov-
erage, and make this an accessible technology for clinical 
practice.
Conclusions
WD represents a very distinct genetic condition where 
mutations in ATP7B interact with copper, diet, and 
metabolism, affecting its complex and varied pheno-
type, so epigenetic indications of disease progression in 
blood or other accessible tissue would clearly be clini-
cally useful. These DMRs likely represent an epigenomic 
signature of WD that includes direct alterations from 
increased copper levels, responses to disease progression, 
and inputs from the environment such as diet. In addi-
tion, the identification of DNA methylation changes over 
genes encoding drug-targetable epigenetic modifiers, 
such as HDAC5, may reveal insights into repurposing of 
existing medications in WD treatment.
Methods
Human liver biopsies
Samples from patients with WD were obtained from 
the University of Heidelberg (Heidelberg, Germany) 
and the California Pacific Medical Center, Ibrahim El-
Hefni Biorepository (San Francisco, California, USA). 
The liver samples from University of Heidelberg were 
derived from explanted livers of patients with WD who 
underwent liver transplant. Liver samples from Califor-
nia Pacific Medical Center were obtained through per-
cutaneous liver biopsies performed for diagnostic and 
staging purposes. Liver samples from DC and HC sub-
jects were obtained from the California Pacific Medical 
Center and the University of California, Davis GI biobank 
(Additional file  1: Table  S1, Additional file  2: Table  S2). 
DC percutaneous liver biopsies were taken from patients 
with NAFLD. HC liver biopsies were obtained at the time 
of bariatric surgery from subjects without diabetes, with 
less than 5% steatosis and no inflammation on histology. 
Biopsies were graded on inflammation, steatosis, and 
inflammation as previously described [41].
Human whole blood samples
Samples from patients with WD (different groups than 
patients providing liver biopsies) were obtained from the 
Institute of Psychiatry and Neurology (Warsaw, Poland). 
HC samples were obtained from volunteers in Warsaw 
and the local Sacramento community. DC samples were 
obtained from patients with a diagnosis of NAFLD and 
PSC who presented consecutively for evaluation at UC 
Davis Hepatology clinic and consented to provide whole 
blood for DNA extraction to be stored in UC Davis GI 
Division Biobank. NAFLD and PSC were chosen as DC 
as both conditions should be considered in the differ-
ential diagnosis of WD, NAFLD patients present epige-
netic changes, and PSC is associated also with copper 
accumulation. In the HC and WD groups, whole blood 
samples were matched by age, sex, and BMI (Additional 
file  1: Table  S10, Additional file  2: Table  S11). Patients 
with other chronic liver diseases (including hepatitis B or 
C, autoimmune hepatitis, alcoholic liver disease, primary 
biliary cholangitis, hemochromatosis) were excluded. 
Patients with WD were recruited at the time of diagnosis, 
determined by Leipzig criteria, and, accordingly, were not 
on anti-copper treatment. WD patients in the test cohort 
were selected to have the ATP7B H1069Q missense 
mutation. Patients were categorized according to their 
prevalent phenotype as having hepatic or neurologic 
presentation. All samples were de-identified, shipped on 
dry ice, and stored at − 80 °C for further analysis.
Whole‑genome bisulfite sequencing (WGBS) and analysis
WGBS libraries were prepared from bisulfite-converted 
DNA using the TruSeq DNA Methylation kit (Illumina, 
San Diego, CA, USA). Libraries from liver and blood train-
ing samples were sequenced on the HiSeq4000, while 
libraries from blood test samples were sequenced on the 
HiSeq2000 (Illumina, San Diego, CA, USA). Reads were 
aligned to the hg38 reference genome, and DMRs were 
identified between HC, WD, and DC samples. All code for 
WGBS data analysis is available on GitHub (https ://githu 
b.com/cemor daunt /Wilso nDise aseEp igeno me).
Additional methods about WGBS data analysis and 
mouse model studies are presented in Additional file  1: 
Supplemental methods.
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